FinancialBuzz.com’s latest Beehind the Buzz Show: Featuring Q BioMed Inc. Chairman and Chief Executive Officer Denis Corin
Q BioMed Inc. (OTCQB: QBIO) aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry-leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets.
Mr. Denis D. Corin is Chief Executive Officer and Chairman of the Board. Mr. Corin is an experienced public company executive and management consultant. He has worked almost exclusively in the biomedical field for over 13 years from large pharma and diagnostic companies to small innovative biotech. He has served in various senior executive roles and has been instrumental in building and restructuring businesses.
Now in its 22nd year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
Cancer is among one of the leading causes of death around the globe; namely, in 2018, there were a total estimated 18.1 million new cases worldwide. The International Agency for Research on Cancer (IARC) projects that one-in-five men and one-in-six women will develop cancer over their lifetime. The agency also suggests that the rising number of cancer cases is correlated to a growing and aging population, in combination with exposure to risk factors associated with social and economic development. The most common types of cancer are lung, breast, and colorectal. The concern over the growing number of patients diagnosed with cancer is causing a demand for effective treatments to rise. As a result, biotechnology companies are developing various new treatments, drugs, and therapies to decelerate or eradicate cancer. According to data compiled by GBI Research, the global oncology market revenue is expected to grow to USD 241 Billion in 2023 from USD 118.6 Billion in 2016. It is also expected to grow at a CAGR of 10.66%. The oncology pipeline is large and very diverse, containing over 7,000 different products. However, the number of cases is still rising, which is responsible for the growing demand for new remedies.
Throughout the process of cancer treatments, patients suffer from symptoms associated with cancer itself or the therapy. Common side effects include vomiting, inflammation, and pain, but companies involved in the oncology and immunotherapy industry have developed numerous palliative medications to aid with the symptoms. The medications most commonly used include analgesics, antiemetics, antidepressants, and steroids. Other variations of treatments, such as chemotherapy or radiotherapy, are intended to slow or control the spread of cancer rather than treating the associated symptoms or curing cancer itself. “Today new avenues for cancer diagnostics and therapeutics present themselves. The choices include specific diagnostics, such as the rapidly evolving use of liquid biopsies that analyze cells and molecules spawned by the tumor and found in bodily fluids such as blood or urine, a more focused analysis of non-responders, the financial implications of future therapies, and an advocacy for a return to basic scientific research. The result of exploring these options will be a wider range of treatment choices for oncologists and a more positive outcome for patients,” said Steve Brozak, President of WBB Securities, LLC, an investment bank and research firm that specializes in the biotechnology, specialty pharmaceutical and medical device sectors.
For more information, please visit: Q BioMed Inc.
About Beehind the Buzz: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.